Global Information Inc. would like to present a new market research report, "Global Markets for Treatments for Syndromes of Dementia and Movement Disorders" by BCC Research.
The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
The market for neurodegenerative disorder treatments can be broken down into three segments: progressive dementia, progressive dementia with other neurological abnormalities, and movement disorders.
Progressive dementia treatments are expected to have a value of $7.3 billion in 2012 and nearly $11 billion in 2017, a CAGR of 8.4%.
Treatments for progressive dementia with other neurological abnormalities should total $537.2 million in 2012 and $913.7 million in 2017, a CAGR of 11.2%.
Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%.
Despite exciting advances in the treatment of syndromes of dementia and movement disorders during the past three years, a complete curative therapy or drug product has not been discovered to date. This is primarily due to the multifarious nature of the diseases and the fact that most of their underlying causes are still unknown or being studied. A number of drug products are in the market; however, these drugs are largely for the symptomatic treatment of these diseases. Thus, there is an urgent need for treatments for the neurodegenerative diseases affecting millions of people worldwide.
This report will help its readers:
- Gain an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders
- Breakdown revenues by neurodegenerative disease and primary clinical/pathological feature
- Review applications for treatments and therapeutic technologies for syndromes of dementia and movement disorders
- Identify the major players in the industry most likely to compete well now and into the future
- Review patent information relevant to the industry.
This study contributes to the areas of market growth in treatments for Alzheimers disease, Lewy body dementia, Picks disease, Huntingtons disease, corticobasal ganglionic degeneration, Parkinsons disease, multiple system atrophy, progressive supranuclear palsy, and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes, and physicians will find this study to be of interest.